RNA Editing (ADAR) Patents

RNA editing patents cover ADAR-recruiting guide-oligonucleotide innovations; guide-chemistry and design innovations; AAV-delivered and engineered-ADAR innovations; and target and delivery innovations — with IP held by RNA-editing-therapeutic companies (in a field that edits RNA, not DNA, using the body's own enzyme). WHAT IS ADAR RNA EDITING: ADAR (Adenosine Deaminase Acting on RNA) is an ENDOGENOUS human enzyme that converts adenosine (A) to inosine (I) in double-stranded RNA — and inosine is read by the cell as guanosine (G), so ADAR makes a functional A-to-G edit; RNA-editing therapeutics use a GUIDE OLIGONUCLEOTIDE (an antisense-like RNA) to recruit the patient's OWN ADAR to a chosen site in a target RNA and make a specific A-to-I edit — WITHOUT cutting DNA, WITHOUT delivering a foreign editing protein, and the edit is on RNA (transient, reversible, re-doseable — a safety profile distinct from permanent DNA editing). MAJOR ADAR RNA-EDITING PATENT HOLDERS: WAVE LIFE SCIENCES: AIMers (ADAR-recruiting oligonucleotides) and WVE-006 (for alpha-1 antitrypsin deficiency AATD) — the first clinical proof-of-concept; Wave's stereopure-chemistry estate applies here. KORRO BIO: the OPERA platform (ADAR-recruiting oligonucleotides). ProQR THERAPEUTICS: the Axiomer ADAR-editing platform. SHAPE THERAPEUTICS: RNAfix — AAV-delivered ADAR-recruiting guide RNAs (a genetic-medicine delivery approach). OTHERS: Ascidian Therapeutics (RNA exon editing — replacing whole exons in RNA), AIRNA, and Beam (which also explores RNA editing). ADAR-recruiting guide oligonucleotides, guide chemistry, AAV-delivered guides, and engineered ADAR are the core RNA-editing patent domains.

ADAR-recruiting guide-design innovations; oligonucleotide-chemistry innovations; editing-efficiency and specificity innovations; and engineered-ADAR innovations represent core RNA-editing patent domains — and the guide oligonucleotide (which recruits endogenous ADAR to the right spot) is the central, valuable invention. GUIDE-DESIGN PATENTS: the antisense guide RNA that base-pairs with the target RNA, creating the double-stranded structure (with a mismatch at the target A) that recruits ADAR to make the edit — guide length, the central mismatch/bulge design (which positions ADAR), recruitment motifs (some guides include an ADAR-recruiting hairpin/domain), and target-site selection (which A to edit, in which transcript). OLIGONUCLEOTIDE-CHEMISTRY PATENTS: the chemical modifications that stabilize the guide and make it drug-like (sharing chemistry with antisense oligonucleotides — 2′-OMe/2′-F, phosphorothioate, and STEREOPURE backbones — Wave) while preserving ADAR recruitment; the modification pattern is high-value, defensible composition IP. EFFICIENCY / SPECIFICITY PATENTS: maximizing on-target editing while minimizing OFF-TARGET editing (ADAR can edit other adenosines in the duplex or elsewhere — bystander editing is a key safety concern), guide designs that improve precision, and reducing immunogenicity. ENGINEERED-ADAR PATENTS: alternatively, delivering an engineered/exogenous ADAR (or its catalytic domain) fused to a guide-binding protein (a more CRISPR-like approach) — though the elegance of harnessing ENDOGENOUS ADAR (no foreign protein) is a key advantage and IP theme. The ADAR-recruiting guide design and its drug-like chemistry (with minimal off-target editing) are the highest-value RNA-editing IP.

Delivery innovations; AAV-encoded guide innovations; target and indication innovations; and durability and re-dosing innovations represent additional RNA-editing patent domains — and ADAR editing's distinct profile (RNA, endogenous enzyme, reversible) shapes its IP versus CRISPR DNA editing. RNA EDITING vs CRISPR DNA EDITING: CRISPR/base/prime editing changes DNA permanently using a foreign Cas protein (durable but irreversible, with immunogenicity and off-target/double-strand-break concerns); ADAR RNA editing changes RNA transiently using the body's OWN enzyme (reversible, re-doseable, no permanent genomic change, no foreign protein — a safety advantage, but requires repeat dosing because the edit fades) — so the two are complementary, and ADAR's value proposition (safety, reversibility, no foreign protein) drives its IP. DELIVERY PATENTS: delivering the guide oligonucleotide — GalNAc conjugation (liver, like siRNA/ASO), lipid nanoparticle, intrathecal (CNS), and AAV-encoded guides (Shape — durable expression of the guide); delivery shares heritage with ASO/siRNA (FTO consideration). TARGET / INDICATION PATENTS: specific A-to-I edits that correct a G-to-A disease mutation (reverting a pathogenic mutation), upregulate a protein, or create a beneficial change — the edit-target-indication combination as method-of-treatment. DURABILITY / RE-DOSING PATENTS: extending the duration of the transient edit and re-dosing regimens (since RNA edits fade). Delivery (GalNAc/AAV-guide), specific therapeutic edits, and durability are high-value RNA-editing IP; the endogenous-ADAR (no-foreign-protein) approach is the differentiating theme.

RNA editing startup IP strategy must navigate Wave/Korro/ProQR ADAR-recruiting-guide estates, antisense-oligonucleotide chemistry IP (the guide chemistry overlaps ASO — Ionis and others), foundational ADAR-recruiting academic prior art (Stafforst and others described ADAR recruitment), siRNA/ASO delivery IP (GalNAc, LNP — FTO), CRISPR/DNA-editing as a competing modality, a §101-light landscape (concrete oligonucleotides), and a landscape where the guide design/chemistry, off-target control, delivery, and the endogenous-enzyme advantage are the durable assets; understand that the ADAR-recruiting concept has foundational/academic IP, that the durable startup IP is in specific guide designs/chemistries, off-target-minimizing precision, delivery, and therapeutic edit-target combinations, and that the no-foreign-protein safety profile is the strategic positioning; identify whitespace in precise guide chemistries, off-target control, AAV-guide delivery, and novel edit targets. ADAR RNA-EDITING STARTUP IP STRATEGY: GUIDE DESIGN/CHEMISTRY, OFF-TARGET CONTROL, AND DELIVERY ARE THE IP — RECRUITMENT CONCEPT IS FOUNDATIONAL: the ADAR-recruiting concept has academic/foundational prior art (Stafforst) and the chemistry overlaps ASO — patent the specific guide design, drug-like (stereopure) chemistry, off-target-minimizing precision, and delivery; THE ENDOGENOUS-ADAR (NO FOREIGN PROTEIN, REVERSIBLE) PROFILE IS THE STRATEGIC ADVANTAGE: harnessing the body's own enzyme avoids foreign-protein immunogenicity and permanent DNA change (a safety advantage over CRISPR) — position and patent around this; OFF-TARGET (BYSTANDER) EDITING CONTROL IS A KEY, PATENTABLE SAFETY PROBLEM: ADAR can edit unintended adenosines — guide designs that improve precision are high-value, defensible IP; DELIVERY (GalNAc/LNP/AAV-GUIDE) DETERMINES DURABILITY AND REACH: GalNAc (liver), AAV-encoded guides (durable, Shape), and extrahepatic delivery are valuable — but clear ASO/siRNA delivery FTO; THERAPEUTIC EDIT-TARGET COMBINATIONS ARE METHOD/COMPOSITION IP: a specific edit correcting a disease mutation or upregulating a protein is protectable; RE-DOSING IS A FEATURE, NOT A BUG — BUT DURABILITY IS A FRONTIER: RNA edits fade (enabling re-dosing/reversibility, a safety plus) — extending duration is patentable; WHEN TO PATENT: NOVEL GUIDE/EDIT WITH MEASURED PERFORMANCE: file once a guide/edit shows measured results (on-target editing % + off-target/bystander profile + duration + delivery + functional/therapeutic effect) — measured editing efficiency, off-target precision, duration, and therapeutic effect are the critical RNA-editing IP metrics; KEY FTO CHECKLIST: Wave AIMers stereopure ADAR-recruiting oligonucleotide WVE-006 AATD; Korro OPERA; ProQR Axiomer; Shape RNAfix AAV-encoded guide; Ascidian RNA exon editing; ADAR-recruiting guide design central-mismatch/recruitment-motif (Stafforst foundational); 2'-OMe/2'-F/phosphorothioate/stereopure chemistry (ASO FTO Ionis); off-target/bystander editing precision; GalNAc/LNP/AAV-guide delivery (siRNA/ASO FTO); endogenous vs engineered/exogenous ADAR; A-to-I edit-target-indication method-of-treatment; RNA editing vs CRISPR DNA editing complementarity.